Daebongls.Co.,Ltd. Share Price

Equities

A078140

KR7078140001

Pharmaceuticals

End-of-day quote Korea S.E. 03:30:00 17/07/2024 am IST 5-day change 1st Jan Change
13,720 KRW -3.38% Intraday chart for Daebongls.Co.,Ltd. +3.47% +49.78%

Financials

Sales 2022 93.5B 67.79M 5.66B Sales 2023 87.62B 63.53M 5.3B Capitalization 102B 73.63M 6.15B
Net income 2022 8.63B 6.26M 522M Net income 2023 4.18B 3.03M 253M EV / Sales 2022 0.26 x
Net cash position 2022 63.99B 46.39M 3.87B Net cash position 2023 41.73B 30.26M 2.53B EV / Sales 2023 0.68 x
P/E ratio 2022
10.1 x
P/E ratio 2023
24 x
Employees 125
Yield 2022
0.63%
Yield 2023
0.55%
Free-Float 47.83%
More Fundamentals * Assessed data
Dynamic Chart
Daebongls.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tranche Update on Daebongls.Co.,Ltd.'s Equity Buyback Plan announced on February 26, 2021. CI
Tranche Update on Daebongls.Co.,Ltd.'s Equity Buyback Plan announced on February 26, 2021. CI
Daebongls.Co.,Ltd.’s Equity Buyback announced on February 26, 2021, has expired with 61,995 shares, representing 0.56% for KRW 616.17 million. CI
Daebongls.Co.,Ltd. announces an Equity Buyback for 100,000 shares, for KRW 986 million. CI
Daebongls.Co.,Ltd. authorizes a Buyback Plan. CI
Tranche Update on Daebongls.Co.,Ltd.'s Equity Buyback Plan announced on April 3, 2020. CI
Tranche Update on Daebongls.Co.,Ltd.'s Equity Buyback Plan announced on April 3, 2020. CI
Tranche Update on Daebongls.Co.,Ltd.'s Equity Buyback Plan announced on April 3, 2020. CI
Daebongls.Co.,Ltd.’s Equity Buyback announced on April 3, 2020, has expired with 76,415 shares, representing 0.69% for KRW 727.29 million. CI
P&K Skin Research Center Co., Ltd. has completed an IPO in the amount of KRW 40.8639 billion. CI
P&K Skin Research Center Co., Ltd. has filed an IPO. CI
Daebongls.Co.,Ltd. announces an Equity Buyback for KRW 1,000 million worth of its shares. CI
More news
1 day-3.38%
1 week+3.47%
Current month+25.76%
1 month+23.16%
3 months+42.92%
6 months+51.77%
Current year+49.78%
More quotes
1 week
12 610.00
Extreme 12610
14 660.00
1 month
10 360.00
Extreme 10360
15 700.00
Current year
8 490.00
Extreme 8490
15 700.00
1 year
7 740.00
Extreme 7740
15 700.00
3 years
6 860.00
Extreme 6860
15 700.00
5 years
4 025.00
Extreme 4025
16 200.00
10 years
4 025.00
Extreme 4025
17 900.00
More quotes
Managers TitleAgeSince
Founder 79 08/86/08
Chief Executive Officer 53 01/01/01
Director/Board Member 56 -
Members of the board TitleAgeSince
Chief Executive Officer 53 01/01/01
Corporate Officer/Principal 56 01/04/01
Founder 79 08/86/08
More insiders
Date Price Change Volume
17/24/17 13,720 -3.38% 1 470 522
16/24/16 14,200 +4.80% 1,570,103
15/24/15 13,550 +2.89% 2,634,773
12/24/12 13,170 -4.70% 1,009,344
11/24/11 13,820 +0.36% 2,492,186

End-of-day quote Korea S.E., July 17, 2024

More quotes
Daebongls. Co., Ltd. is a Korea-based company engaged in the manufacture of raw materials for pharmaceuticals and cosmetics. The Company operates its business through two main divisions: cosmetic division, which provides aloe vera gels, beta carotens, calamines, diaformers, emulgades and others for conditioners, emulsifiers, emollients, polymers, thickeners and others; pharmaceutical division, which provides almagates, bentonites, calcitriols, erdosteines, fish oil and others for antibiotics, cough products, expectorants and others. In addition, it is involved in the provision of food chemical additives, fish feedstuff and others. The Company distributes its products within domestic market and to overseas markets, including Japan, America and other Southeast Asian countries.
More about the company
  1. Stock Market
  2. Equities
  3. A078140 Stock